Cynomolgus Complement C5 Protein, Tag Free

内毒素:
Less than 1.0 EU per μg by the LAL method.

纯度:
>95% as determined by SDS-PAGE.

活性:
Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus Complement C5, Tag Free (Cat. No. CO5-C5217) at 2 μg/mL (100 μL/well) can bind Bevacizumab with a linear range of 0.8-6 ng/mL (QC tested).

产品背景:
Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. C5 precursor is first processed by the removal of 4 basic residues, forming two chains, beta and alpha, linked by a disulfide bond. C5 convertase activates C5 by cleaving the alpha chain, releasing C5a anaphylatoxin and generating C5b (beta chain + alpha' chain). Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. The C5a anaphylatoxin interacts with CR1 and tick complement inhibitor. C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

产品描述:
This protein carries no "tag". The protein has a calculated MW of 73.4 kDa (β chain) & 113.4 kDa (α chain). The protein migrates as 68 kDa and 113 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
因为难以在供应系统上进行数据同步//所以了解更多产品规格及产品数据//请移步：
http://www.acrobiosystems.cn/P1548-Cynomolgus_Complement%A0C5_Protein_Tag_Free.html